Mark Gilbert – Juno Therapeutics

Mark Gilbert, M.D.

SVP, Chief Medical Officer

Mark J. Gilbert is our Chief Medical Officer and joined Juno in March 2014. Prior to joining Juno, Dr. Gilbert served as an interim CMO or consultant in strategic drug development and portfolio management in medical oncology for several US biotech and pharmaceutical companies. Previously, Dr. Gilbert served as Vice President and Head Global Clinical Development, Therapeutic Area Oncology, at Bayer Schering Pharmaceuticals. Prior to Bayer Schering, he held several executive positions with Berlex Pharmaceuticals and its parent company Schering, AG, mostly as Vice President and Head of Global Medical Development Group, Oncology. Dr. Gilbert joined Berlex from Immunex, where his responsibilities included development and medical affairs for Leukine and Mitoxantrone in hematology, oncology, Crohn’s disease, and multiple sclerosis. Dr. Gilbert received a B.S. in Biochemistry from the University of Iowa and his M.D. from the University of Iowa Medical School and trained in internal medicine, infectious disease, and medical oncology at the University of California, San Francisco, and the University of Washington, respectively. Prior to his executive positions in biotech and oncology companies, Dr. Gilbert was a faculty member at the Fred Hutchinson Cancer Research Center and the University of Washington and trained in the laboratory of Dr. Phil Greenberg, one of our scientific co-founders.